Merck & Co., Inc. stock (US58933Y1055): Is Keytruda's dominance strong enough to unlock new upside?

With Keytruda driving massive revenue, you need to know if Merck's oncology leadership can sustain growth amid patent cliffs and rivals. This matters for U.S. investors seeking defensive healthcare plays with innovation potential. ISIN: US58933Y1055

Merck & Co., Inc. stands as a pharmaceutical powerhouse, particularly through its blockbuster cancer drug Keytruda, which generates the bulk of its revenue and positions the stock as a key holding for investors in the United States and across English-speaking markets worldwide. You rely on companies like Merck for stable growth in healthcare, a sector that offers resilience during economic uncertainty. The question is whether its oncology dominance translates into sustained shareholder value as competition heats up.

Updated: 15.04.2026

By Elena Vargas, Senior Healthcare Stock Editor – Merck's blend of innovation and market leadership makes it a watchlist staple for long-term portfolios.

Merck's Core Business Model and Revenue Engine

Merck operates a diversified pharmaceutical model centered on human health solutions, with a heavy emphasis on oncology, vaccines, and hospital medicines. Keytruda, its PD-1 inhibitor, accounts for over 40% of total sales, underscoring the company's reliance on this immunotherapy leader approved for multiple cancer indications. This focus allows Merck to capture high-margin recurring revenue from chronic treatments, appealing to you as an investor seeking predictable cash flows.

Beyond oncology, Merck's portfolio includes Gardasil for HPV prevention, Januvia for diabetes, and animal health products under its legacy Organon spin-off structure, though human pharma drives the majority. The business model emphasizes R&D investment, strategic partnerships, and global distribution to maintain a competitive edge in a highly regulated industry. For U.S. readers, this means exposure to domestic blockbuster drugs while benefiting from international expansion.

Merck's scale enables cost efficiencies in manufacturing and marketing, helping it weather pricing pressures from U.S. healthcare reforms. You see this model as robust because it balances high-growth areas like immuno-oncology with stable vaccine sales, providing a defensive tilt in volatile markets. The company's ability to reinvest profits into a deep pipeline sustains long-term viability.

Key Products Driving Growth and Market Position

Keytruda remains Merck's growth engine, with label expansions into earlier-stage cancers and new combinations boosting adoption among oncologists worldwide. This drug's versatility across tumor types creates a wide moat through clinical data superiority and first-mover advantage in PD-1 therapy. You benefit as an investor from its pricing power and volume growth in both U.S. and ex-U.S. markets.

Gardasil 9, the next-generation HPV vaccine, targets a massive preventable cancer market, with strong demand from public health programs. Winrevair, a recent cardiovascular approval, adds diversification into pulmonary arterial hypertension, a high-unmet-need area. These products position Merck competitively against rivals like Pfizer and Bristol Myers Squibb, particularly in oncology where combination therapies are the future.

Merck's animal health segment, though smaller post-spin-off, provides steady revenue from livestock and companion animal products. For readers in the United States, these offerings align with domestic agricultural needs and pet ownership trends, enhancing overall stability. The pipeline, with over 80 programs, signals ongoing innovation to replace maturing assets.

Analyst Views on Merck's Valuation and Outlook

Analysts from major institutions view Merck as a wide-moat stock with strong fundamentals, often highlighting its competitive advantage period in oncology as a key value driver, similar to frameworks assessing how long firms sustain returns above cost of capital. Reputable research emphasizes Keytruda's durability against biosimilars and the promise of next-gen assets like MK-1084. Coverage consistently rates the stock as a hold to buy, citing pipeline depth offsetting patent losses.

This perspective resonates for you in the United States, where healthcare spending growth supports Merck's domestic sales. Banks note the company's balance sheet strength enables acquisitions and dividends, making it attractive for income-focused portfolios. Overall, consensus leans positive on long-term execution, though near-term biosimilar risks temper enthusiasm.

Investor Relevance in the United States and English-Speaking Markets

For you as a U.S. investor, Merck offers direct exposure to the world's largest pharma market, where Medicare negotiations impact pricing but innovation protects margins. The stock's inclusion in major indices like the Dow Jones provides broad market participation with dividend reliability. English-speaking markets worldwide, including the UK and Canada, mirror U.S. trends in cancer care, amplifying Merck's global footprint.

Healthcare reforms like the Inflation Reduction Act introduce price controls on select drugs, but Merck's diverse portfolio mitigates this. You value the company's U.S.-centric R&D hubs and manufacturing, ensuring supply chain resilience amid geopolitical tensions. This positions Merck as a core holding for defensive growth in retirement accounts and 401(k)s.

Across English-speaking regions, rising cancer incidence drives demand for Keytruda, with public health systems favoring proven therapies. Merck's advocacy for patient access enhances its reputation, indirectly supporting stock stability. You should consider its role in diversified portfolios balancing tech volatility.

Risks and Open Questions Facing Merck

The looming Keytruda patent expiry in 2028 poses the biggest risk, potentially eroding billions in revenue as biosimilars enter. Merck counters with subcutaneous formulations and combinations, but execution is critical. You must watch regulatory hurdles for pipeline candidates, where FDA scrutiny on safety could delay launches.

Competition from Roche's Tecentriq and emerging ADCs intensifies pressure on market share. Pricing reforms in the U.S. and Europe squeeze margins, challenging profitability. Supply chain disruptions, especially for biologics, remain a vulnerability in global operations.

Open questions include the success of new modalities like ADCs and radiopharma, plus M&A integration risks. For U.S. investors, policy shifts post-elections could alter drug pricing dynamics. Overall, these factors demand vigilant monitoring from you.

Industry Drivers and Competitive Position

Pharma industry tailwinds include aging populations and precision medicine advances, favoring Merck's targeted therapies. Oncology spending surges globally, with immuno-oncology leading. Merck's moat stems from R&D scale and partnerships, like with Moderna on cancer vaccines.

Against peers, Merck excels in execution, boasting higher ROIC sustained over cycles, akin to analyses of competitive advantage periods. Its U.S. market share in key segments provides leverage. You appreciate this positioning for weathering downturns.

Strategic shifts toward biosimilars defense and diversification build resilience. The company's focus on unmet needs differentiates it, supporting premium pricing power.

What You Should Watch Next

Track Keytruda trial readouts and label expansions, as they could extend revenue life. Monitor Q4 earnings for pipeline updates and guidance. Regulatory decisions on Winrevair uptake and new filings will signal growth potential.

For U.S. readers, watch PBM negotiations and IRA impacts. Dividend hikes or buybacks reflect confidence. Broader market reactions to Fed policy affect healthcare valuations.

Long-term, assess M&A for bolt-ons in high-growth areas. These catalysts will shape whether Merck delivers upside or faces headwinds.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.